Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells

BACKGROUND: Breast cancer (BC) cells secrete soluble factors that accelerate osteoclast (OC) differentiation, leading to the formation of osteolytic bone metastases. In the BOLERO-2 trial, BC patients with bone involvement who received Everolimus had a delayed tumor progression in the skeleton as a...

詳細記述

保存先:
書誌詳細
出版年:BMC Cancer
主要な著者: Simone, Valeria, Ciavarella, Sabino, Brunetti, Oronzo, Savonarola, Annalisa, Cives, Mauro, Tucci, Marco, Opinto, Giuseppina, Maiorano, Eugenio, Silvestris, Franco
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2015
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4606500/
https://ncbi.nlm.nih.gov/pubmed/26468083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1717-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料